[go: up one dir, main page]

WO2023106777A1 - Melon vital (kctc14699bp) et composition anti-obésité comprenant un extrait de celui-ci - Google Patents

Melon vital (kctc14699bp) et composition anti-obésité comprenant un extrait de celui-ci Download PDF

Info

Publication number
WO2023106777A1
WO2023106777A1 PCT/KR2022/019662 KR2022019662W WO2023106777A1 WO 2023106777 A1 WO2023106777 A1 WO 2023106777A1 KR 2022019662 W KR2022019662 W KR 2022019662W WO 2023106777 A1 WO2023106777 A1 WO 2023106777A1
Authority
WO
WIPO (PCT)
Prior art keywords
melon
vital
extract
obesity
preventing
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/KR2022/019662
Other languages
English (en)
Korean (ko)
Inventor
최영환
강남준
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Kwang Dong Pharmaceutical Co Ltd
Original Assignee
Kwang Dong Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kwang Dong Pharmaceutical Co Ltd filed Critical Kwang Dong Pharmaceutical Co Ltd
Publication of WO2023106777A1 publication Critical patent/WO2023106777A1/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01H—NEW PLANTS OR NON-TRANSGENIC PROCESSES FOR OBTAINING THEM; PLANT REPRODUCTION BY TISSUE CULTURE TECHNIQUES
    • A01H1/00—Processes for modifying genotypes ; Plants characterised by associated natural traits
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01H—NEW PLANTS OR NON-TRANSGENIC PROCESSES FOR OBTAINING THEM; PLANT REPRODUCTION BY TISSUE CULTURE TECHNIQUES
    • A01H1/00—Processes for modifying genotypes ; Plants characterised by associated natural traits
    • A01H1/02—Methods or apparatus for hybridisation; Artificial pollination ; Fertility
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01H—NEW PLANTS OR NON-TRANSGENIC PROCESSES FOR OBTAINING THEM; PLANT REPRODUCTION BY TISSUE CULTURE TECHNIQUES
    • A01H6/00—Angiosperms, i.e. flowering plants, characterised by their botanic taxonomy
    • A01H6/34—Cucurbitaceae, e.g. bitter melon, cucumber or watermelon 
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/135—Bacteria or derivatives thereof, e.g. probiotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/42—Cucurbitaceae (Cucumber family)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents

Definitions

  • the present invention relates to a composition for preventing, treating, or improving obesity or metabolic-related diseases, including vital melon (KCTC14699BP) and an extract thereof.
  • vital melon KCTC14699BP
  • NASH non-alcoholic fatty liver
  • the inventors of the present invention found that when melons and cultivated melons are hybridized during research to obtain new useful crops, melons of new varieties can be produced that can overcome the low productivity of melons while increasing the useful activity of melons. It was confirmed, and furthermore, it was confirmed that the extract of the new variety identified in the present invention exhibits an excellent anti-obesity effect, and the present invention was completed.
  • an object of the present invention is to provide a pharmaceutical, food, and health functional food composition comprising vital melon having an anti-obesity effect and the vital melon extract.
  • the present invention is a) the number of nodes in the main and side branches; and b) a vital melon with accession number KCTC14699BP having the same characteristics as having high cucurbitacin A and cucurbitacin B content compared to melon varieties ( Cucumis melo L. var. vitalmelon).
  • the present invention is a parental melon ( Cucumis ) self-fertilized 5 to 10 times with the characteristics of epiphytic female flowers for each node and the characteristics of benignization as the target trait.
  • melo var. makuwa Makino and cultivar melons ( Cucumis melo var. reticulatus) self-fertilized 5 to 10 times with target traits for leaflet characteristics and large fruits; Accession number containing a vital melon ( Cucumis melo L. var. vitalmelon ).
  • the present invention provides a pharmaceutical composition for preventing or treating obesity or metabolic diseases containing an extract of vital melon (accession number KCTC14699BP).
  • the present invention provides a health functional food composition for preventing or improving obesity or metabolic diseases, including an extract of vital melon (accession number KCTC14699BP).
  • the present invention provides a food composition for preventing or improving obesity or metabolic diseases containing an extract of vital melon (accession number KCTC14699BP).
  • the present invention provides a quasi-drug composition for preventing or improving obesity or metabolic diseases containing an extract of vital melon (accession number KCTC14699BP).
  • the present invention provides a method for preventing, improving, or treating obesity or metabolic disease, comprising administering an extract of vital melon (accession number KCTC14699BP) to a subject in need thereof.
  • an extract of vital melon accession number KCTC14699BP
  • the present invention provides an extract of vital melon (accession number KCTC14699BP) for preventing, improving, or treating obesity or metabolic diseases.
  • the present invention provides the use of an extract of vital melon (Accession No. KCTC14699BP) for producing a drug for preventing, improving, or treating obesity or metabolic diseases.
  • an extract of vital melon (Accession No. KCTC14699BP) for producing a drug for preventing, improving, or treating obesity or metabolic diseases.
  • the vital melon of the present invention bears fruit as much as the number of nodes of the main branch and side branches, and can obtain larger fruits than conventional melons, so not only is it excellent in productivity, but its extract prevents lipid accumulation, weight gain, and fat accumulation in the liver. Since it can effectively inhibit, it can be used as a composition for preventing, improving or treating various obesity or metabolic diseases.
  • 1 is a view showing the appearance of the vital melon (KCTC14699BP) of the present invention obtained by hybridizing the parent melon with the parent cultivated melon.
  • Figure 2 is a view showing the results confirming the effect of inhibiting fat cell differentiation and lipid accumulation of vital melon water extract (Hybrid (F1)), melon (mother, M), and cultivated melon (Father, F).
  • a in FIG. 2 is a photograph confirming the effect using a camera and a microscope after staining with Oil Red O
  • B in FIG. 2 is a graph in which the effect is quantitatively analyzed using an ELISA reader.
  • Figure 3 is a diagram showing the results of confirming the effect of inhibiting glucose absorption (A) and triglyceride accumulation (B) in cells according to the concentration of vital melon water extract (VW) (The values with different letters indicate significant differences as determined by Duncan's multiple range test (p ⁇ 0.05)).
  • Figure 4 is a diagram showing the results of confirming changes in plasma liver enzymes, lipid levels, total protein and glucose according to the positive control group orlistat or vital melon water extract (VW) diet in high fat diet mice (HFD). .
  • FIG. 5 is a view showing the results of confirming changes in insulin, leptin, and adiponectin according to the positive control group, orlistat (OT10) or vital melon water extract (VW) diet in high-fat diet mice (HFD).
  • orlistat OT10
  • VW vital melon water extract
  • FIG. 6 is a view showing the results of confirming the effect of inhibiting liver fat accumulation according to the positive control, orlistat (OT10) or vital melon water extract (VW) diet in high-fat diet mice (HFD).
  • FIG. 7 is a view showing the results of confirming the fat cell size inhibitory effect according to the diet of orlistat (OT10) or vital melon water extract (VW) as a positive control in high fat diet mice (HFD).
  • FIG. 8 is a view showing the results of confirming the expression changes of PPAR- ⁇ and its target genes LPL, CD35, HMGCR and L-FABP according to treatment with vital melon water extract (VW) in 3T3-L1 cells.
  • Figure 9 is a diagram showing the results of confirming the expression changes of PPAR- ⁇ and its target genes LPL, CD36, HMGCR and L-FABP according to treatment with vital melon water extract (VW) in the liver of mice on a high fat diet.
  • VW vital melon water extract
  • the present invention has accession number KCTC14699BP vital melon ( Cucumis melo L. var. vitalmelon ).
  • the vital melon is a) as much as the number of nodes in the main and side branches; and b) a high content of cucurbitacin A and cucurbitacin B compared to melon varieties.
  • the parental melon can use melons self-fertilized 5 to 10 times, preferably 6 to 8 times, with the characteristics of epiphytic female flowers per node and the characteristics of benignization as the target trait.
  • Cultivated melons can be self-pollinated cultivated melons 5 to 10 times, preferably 6 to 8 times, with the characteristics of lobules and large fruits as the target traits.
  • the traits of the mother and father can be fixed through the repeated self-fertilization process as described above.
  • the first-generation seeds obtained through hybridization were uniformly and stably expressed in the target trait, and it was confirmed that they were new varieties that exhibited characteristics different from those of the mother and father. It was entrusted to the Korea Research Institute of Bioscience and Biotechnology on 2021.09.13 and was given the KCTC14699BP number.
  • the present invention is a parental melon ( Cucumis ) self-fertilized 5 to 10 times with the characteristics of epiphytic female flowers and benignization characteristics for each node as target traits.
  • melo var. makuwa Makino and a domestic melon ( Cucumis melo var. reticulatus ) self-fertilized 5 to 10 times with the characteristics of leaflets and large fruits as target traits; Accession number containing a vital melon ( Cucumis melo L. var. vitalmelon ).
  • the vital melon prepared in the present invention can be characterized by having a medium-sized fruit weight between the mother and the female, and high contents of cucurbitacins A and B, which are not found in the female.
  • Cucurbitacin' is a kind of biochemical compound produced in some plants, especially in the Cucurbitaceae family, which includes common pumpkins and gourds, and has a protective action against herbivores, and is known as an active ingredient in cucurbits. there is.
  • the vital melon of the present invention bears the number of nodes on the main and side branches, it can overcome the low productivity of the mother plant.
  • the vital melon of the present invention is characterized as a new variety having the advantage of having a larger fruit size and higher productivity than the mother plant while containing more cucurbitacins A and B, which are effective components, than the parent plant.
  • the present invention can prevent, treat or treat obesity or metabolic disease, including extracts of vital melon (accession number KCTC14699BP).
  • a pharmaceutical composition for improvement, a health functional food composition, a food composition, and a quasi-drug composition are provided.
  • the vital melon of the present invention is a) fruiting by the number of nodes on the main and side branches; and b) it may be a new variety characterized by a higher content of cucurbitacin A and cucurbitacin B compared to melon varieties, using various extraction methods known in the art for use in preventing, treating or improving obesity or metabolic diseases. So, the fruit flesh can be extracted and used.
  • the extract may include all extracts and fractions thereof without limitation.
  • the extract of vital melon may be characterized in that it is extracted with a lower alcohol extract having 1 to 4 carbon atoms or a mixed solvent thereof, preferably extracted with water as an extraction solvent.
  • extraction when extracting vital melon using water as an extraction solvent, extraction can be performed at room temperature, and 10 to 30 times (w / v), preferably 15 to 25 times (w / v) of the vital melon sample
  • An extract obtained by adding distilled water of v) and extracting or ultrasonicating it in a water bath at 60 to 90° C., preferably 75 to 85° C. for 2 to 5 hours may be used.
  • the ultrasonic treatment may be performed 1 to 5 times.
  • the vital melon extract not only exhibits effects of adipocyte differentiation, inhibition of lipid accumulation, inhibition of intracellular glucose absorption, and inhibition of triglyceride accumulation, but also lipid accumulation in the liver induced by a high-fat diet, increase in fat cell size, It was confirmed that all lipid increases in the blood can be effectively suppressed.
  • the vital melon extract of the present invention may exhibit effects of preventing, treating, or improving various metabolic diseases as well as obesity.
  • the metabolic disease is associated with obesity and may include all metabolic diseases widely known in the art without limitation, preferably in the group consisting of obesity, hypertension, arteriosclerosis, hepatic steatosis, fatty liver, dyslipidemia, diabetes and hyperglycemia. It may be one or more selected species.
  • the dyslipidemia may be more specifically one or more selected from the group consisting of hyperlipidemia, hyper-LDL cholesterolemia, hypertriglyceridemia, and hypo-HDL cholesterolemia.
  • the 'vital melon extract' of the present invention may be included in any amount (effective amount) according to the purpose of use, formulation, blending, etc., as long as the active ingredient can exhibit anti-obesity activity. More specifically, when the composition of the present invention is administered to a person during the administration period according to the advice of medical experts, etc., the amount of the active ingredient included in the composition of the present invention that can exhibit the intended functional and pharmacological effects such as anti-obesity effect says Such an effective amount can be determined empirically within the ordinary skill of the skilled artisan.
  • composition of the present invention may further include any compound or natural extract whose safety has already been verified to prevent, treat, or improve obesity or metabolic disease, or increase or enhance activity.
  • the pharmaceutical composition of the present invention can be formulated and used in the form of oral formulations such as powders, granules, tablets, capsules, suspensions, emulsions, syrups, aerosols, external preparations, suppositories and sterile injection solutions according to conventional methods, respectively.
  • Carriers, excipients, and diluents that may be included in the pharmaceutical composition include lactose, dextrose, sucrose, sorbitol, mannitol, xylitol, erythritol, maltitol, starch, gum acacia, alginate, gelatin, calcium phosphate, calcium silicate, and cellulose.
  • diluents or excipients such as commonly used fillers, extenders, binders, wetting agents, disintegrants, and surfactants.
  • Solid preparations for oral administration include tablets, pills, powders, granules, capsules, etc., and these solid preparations contain at least one excipient, for example, starch, calcium carbonate, sucrose or It is prepared by mixing lactose and gelatin.
  • lubricants such as magnesium stearate and talc are also used.
  • Liquid preparations for oral use include suspensions, solutions for oral use, emulsions, syrups, etc.
  • various excipients such as wetting agents, sweeteners, aromatics, and preservatives may be included.
  • Formulations for parenteral administration include sterilized aqueous solutions, non-aqueous solvents, suspensions, emulsions, freeze-dried formulations, and suppositories.
  • Propylene glycol, polyethylene glycol, vegetable oils such as olive oil, and injectable esters such as ethyl oleate may be used as non-aqueous solvents and suspensions.
  • As a base for the suppository witepsol, macrogol, tween 61, cacao butter, laurin paper, glycerogeratin and the like may be used.
  • the dosage of the pharmaceutical composition of the present invention will vary depending on the age, sex, and weight of the subject to be treated, the specific disease or pathological condition to be treated, the severity of the disease or pathological condition, the route of administration, and the judgment of the prescriber. Determination of dosage based on these factors is within the level of those skilled in the art, and generally dosages range from 0.01 mg/kg/day to approximately 2000 mg/kg/day. A more preferred dosage is 1 mg/kg/day to 500 mg/kg/day. Administration may be administered once a day, or may be administered in several divided doses. The dosage is not intended to limit the scope of the present invention in any way.
  • the pharmaceutical composition of the present invention can be administered to mammals such as rats, livestock, and humans through various routes. All modes of administration are contemplated, eg oral, rectal or intravenous, intramuscular, subcutaneous, intrauterine intrathecal or intracerebrovascular injection. Since the compound of the present invention has little toxicity and side effects, it is a drug that can be safely used even when taken for a long period of time for preventive purposes.
  • the vital melon extract of the present invention is a natural extract, it is not toxic to cells and can be used in various ways as health functional food, food, and quasi-drug composition other than pharmaceuticals.
  • the health functional (sex) food is the same term as food for special health use (FoSHU), medicine that is processed to efficiently display bioregulatory functions in addition to nutritional supply, medical care Means highly effective food.
  • “function (sex)” means to obtain useful effects for health purposes such as regulating nutrients for the structure and function of the human body or physiological functions.
  • the food of the present invention can be prepared by a method commonly used in the art, and can be prepared by adding raw materials and ingredients commonly added in the art during the preparation.
  • the formulation of the food may also be prepared without limitation as long as the formulation is recognized as a food.
  • the food composition of the present invention can be prepared in various types of dosage forms, and unlike general medicines, it has the advantage of not having side effects that may occur when taking medicines for a long time by using food as a raw material, and has excellent portability.
  • the health functional food of the present invention includes components commonly added during food preparation, and includes, for example, proteins, carbohydrates, fats, nutrients, and seasonings.
  • a flavoring agent or natural carbohydrate may be included as an additional ingredient in addition to the vital melon extract as an active ingredient.
  • natural carbohydrates include monosaccharides (eg, glucose, fructose, etc.), disaccharides (eg, maltose, sucrose, etc.), oligosaccharides, polysaccharides (eg, dextrins, cyclodextrins, etc.), and and sugar alcohols (eg, xylitol, sorbitol, erythritol, etc.).
  • natural flavoring agents eg, taumarin, stevia extract, etc.
  • synthetic flavoring agents eg, saccharin, aspartame, etc.
  • the health functional food or food of the present invention may be provided in the form of tablets, capsules, pills or liquids, and the form to which the extract of the present invention may be added includes, for example, various drinks, meat, sausages, Bread, candy, snacks, noodles, ice cream, dairy products, soups, ionic beverages, beverages, alcoholic beverages, gum, tea, and vitamin complexes.
  • the present invention provides a method for preventing, improving, or treating obesity or metabolic diseases, comprising administering an extract of vital melon (accession number KCTC14699BP) to a subject in need thereof.
  • an extract of vital melon accession number KCTC14699BP
  • the present invention provides an extract of vital melon (accession number KCTC14699BP) for preventing, improving, or treating obesity or metabolic diseases.
  • the present invention provides the use of extracts of vital melon (Accession No. KCTC14699BP) for producing drugs for preventing, improving, or treating obesity or metabolic diseases.
  • the subject refers to all animals, including humans, who have or are likely to develop obesity or metabolic diseases.
  • the animal may be not only humans but also mammals such as cattle, horses, sheep, pigs, goats, camels, antelopes, dogs, and cats that require treatment for similar symptoms, but are not limited thereto.
  • the method for preventing or treating the metabolic disease may include, in detail, administering the composition in a pharmaceutically effective amount to a subject who has or is likely to have a metabolic disease.
  • Cucumis melo var. reticulatus (CR) and melon ( Cucumis melo var. makuwa Makino) (CM) were fixed and used as a model.
  • the melon ( Cucumis melo var. makuwa Makino) which is the starting variety, has the characteristics of small fruit size, bisexuality, and epiphytic female flowers on each node, and Cucumis , a cultivated melon melo var. reticulatus is a leaflet, and it was confirmed that the fruit size is large.
  • melons were self-fertilized 7 times with the characteristics of melon epiphytic female flowers per node and benignization characteristics as target traits, and through this, the melon traits were fixed.
  • leaflet characteristics and large-fruit characteristics were set as target traits, and the cultivated melons were self-fertilized 7 times to fix the melon traits.
  • Fruits of vital melon were harvested at 10, 20, 30, 40, and 50 days of fruit development based on the mating date and used in subsequent experiments.
  • the vital melon showed a fruit weight larger than that of the parent and smaller than that of the female.
  • the vital melon contained both cucurbitacins A and B, although no cucurbitacins A and B were found in the part.
  • the content of cucurbitacin B was very high for 10 days after fertilization.
  • the vital melon showed the characteristics of the parent melon by settling on the main and side branches, and it was confirmed that it was possible to harvest continuously after fruit set after settling on the main and side branches as much as the number of nodes.
  • 3T3-L1 cell line was purchased from KCLB (Korea Cell Line Bank, Seoul, Korea), 10% FBS (Welgene, Gyeongsan), 25 mM HEPE (Sigma, St Louis, MO, USA) and 25 mM NaHCO 3 (Sigma, St Louis). , MO, USA) in a DMEM culture medium containing 37° C., 5% CO 2 and maintained.
  • DM differentiation medium
  • Distilled water IN + DEX + ROS + DW
  • vital melon water extract VW
  • Example 3 a water extract was prepared and treated in the same manner as with vital melon.
  • Adipogenesis was confirmed by evaluation of lipid accumulation using Oil Red O staining.
  • Oil Red O staining was performed on day 8 after washing the cells with PBS, fixing with 4% formaldehyde, maintaining at room temperature for 30 minutes, and then treating with Oil Red O dye and maintaining at 4° C. for 60 minutes. After staining, the excess amount of staining was removed, and the cells were washed twice with PBS, and then images were taken using a 200 magnification microscope and camera. The results of confirming the inhibition of adipocyte differentiation and lipid accumulation of the vital melon water extract are shown in FIG. 2 .
  • lipid accumulation was suppressed from the concentration of 50 ⁇ g/ml of cultivated melon (Father, F), the parent melon (Mother, M) treatment group and vital melon treatment group (F1) were 1 to 10 ⁇ g/ml.
  • the accumulation of lipids was effectively inhibited from ml.
  • the vital melon treatment group showed a better lipid accumulation inhibitory effect than the mother plant at a low concentration of 1 to 5 ⁇ g/ml.
  • 3T3-L1 cells were placed in differentiation medium (DM), differentiation medium with DMSO (DMSO), or differentiation medium containing water extract of vital melon at different concentrations, and differentiation into adipocytes was induced by day 8. Then, medium was obtained from each well and the glucose concentration on the 8th day was measured. In order to measure the content of glucose contained in the medium, the medium of each well was collected on the 8th day, and they were centrifuged at 1000g for 5 minutes. Glucose present in the supernatant was then quantified using a commercial glucose kit.
  • triglyceride content was measured using a commercial TG kit.
  • the vital melon water extract inhibited the absorption of glucose in the medium into the cells, and inhibited the accumulation of triglycerides.
  • mice Six-week-old C57BL/6 male mice were purchased from Samtako Bio-Korea Inc. (Osan, Korea) and supplied with water and a standard normal diet (10 kcal% fat, Research Diets, New Brunswick, NJ, USA) and a high-fat diet (60 kcal% fat). , Research Diets, New Brunswick, NJ, USA). During the experiment, the mice were maintained in a sterile environment, 23 ⁇ 2%, 50 ⁇ 10% relative humidity, and strict lighting cycle conditions (08:00 on and 20:00 off). All mouse experiments were handled by the Pusan National University-Laboratory Animal Resource Center accredited by the Korean FDA (Accredited Unit no. 000231) and AAALAC International (Accredited Unit no. 001525), and the Pusan National University Animal Ethics Committee (PNU-2020-2709) approved for animal studies. All animals were acclimated to a normal diet (D12450K; Research Diets, New Brunswick, NJ, USA) for one week.
  • a standard normal diet 10 kcal% fat,
  • mice/group A total of 50 C57BL/6 mice were randomly divided into 5 groups (10 mice/group), and the experiment was conducted for 8 weeks by setting the experimental groups as follows: 1) a control group fed a normal diet, 2) a high-fat group HFD group fed diet, 3) OT group fed 10mg/kg Orlistat to high-fat diet (positive control), 4) VW1 group fed 1mg/kg vital melon water extract to high-fat diet, 5) 25mg/kg high-fat diet fed VW25 group provided kg of vital melon water extract.
  • composition of the diet used in the present invention is shown in Table 2.
  • mice The body weight and food intake of the mice were measured every 3 days for 10 weeks at 9 am using an electronic balance (cat. no. AD-2.5; Mettler Toledo, Griesee, Switzerland) according to KFDA guidelines.
  • mice were sacrificed by CO 2 asphyxiation, and blood samples were collected for biochemical analysis. Liver, kidney and adipose tissue were collected from sacrificed C57BL/6 mice, each tissue was weighed, photographed and immediately stored at -70°C until analysis.
  • Table 3 shows the weight change effect according to the treatment of the vital melon water extract.
  • an automatic chemistry analyzer 7180 Automatic Analyzer, Hitachi High-Technology Cor., Tokyo, Japan
  • serum alkaline phosphatase (ALP), alanine aminotransferase (ALT), aspartate aminotransferase (AST), blood urea nitrogen (BUN), and creatinine (Crea) were analyzed using an automatic biochemical analyzer (7180 Automatic Analyzer). ; Hitachi High-Technologies Cor., Tokyo, Japan). All analyzes were repeated twice using fresh serum, and plasma insulin, creatine, leptin, and adiponectin were measured using an ELISA kit. Serum biochemical analysis results are shown in FIGS. 4 and 5 .
  • the plasma liver enzymes AST and ALT of the high-fat diet group were significantly increased compared to the normal diet group (Nor), and in the group fed with the vital melon water extract (VW) compared to HFD It was confirmed that this increase was significantly reduced. In addition, it was confirmed that the increase in lipid levels (total cholesterol, HDL cholesterol, cholesterol, LDL cholesterol, and triglyceride), total protein, and glucose induced by the high-fat diet was improved in the group fed the vital melon water extract.
  • the concentrations of insulin and leptin increased in the high-fat diet group, which was determined to be related to the increase in abdominal fat in the high-fat diet fed group.
  • the increase in insulin concentration was reduced in the OT group, but not to a significant extent.
  • the VW25 group which was fed vital melon for 70 days, it was confirmed that insulin and leptin decreased significantly compared to the HFD group (P ⁇ 0.05).
  • serum adiponectin was increased in the Vitalmelon treated group compared to the HDF group.
  • Liver and adipose tissue were isolated from all subgroups of mice fed by the method of Example 6 and fixed overnight in 10% neutral buffered formaldehyde (pH 6.8). Dehydrated liver tissue was fixed in paraffin wax. Liver and fat sections (4 ⁇ m) were cut from paraffin-embedded tissues using a Leica microtome (cat. no. DM500; Leica Microsystems, Bannockburn, IL, USA). The sections were then deparaffinized with xylene, rehydrated with graded ethanol (100-70% decreasing concentration) and finally washed with distilled water.
  • Leica microtome cat. no. DM500; Leica Microsystems, Bannockburn, IL, USA. The sections were then deparaffinized with xylene, rehydrated with graded ethanol (100-70% decreasing concentration) and finally washed with distilled water.
  • the size of adipocytes in the HFD group was confirmed to be about 100 ⁇ m, which is about 2.7 times higher than about 37 ⁇ m in the normal control group.
  • the fat cell size was about 50 ⁇ m, which is about twice as small as that of the HFD group.
  • all VW-treated groups showed a concentration-dependently significant reduction in fat cell size.
  • the size of adipocytes in the VW-treated group was approximately 65 ⁇ m and 60 ⁇ m, respectively, depending on the concentration (P ⁇ 0.05).
  • Example 9 In vitro, in vitro vivo Protein expression analysis results for the sample
  • PPAR- ⁇ pathway plays an essential role in the differentiation of adipocytes by regulating the transcription of various genes responsible for lipid transport and accumulation. Therefore, an experiment was performed to confirm whether the treatment of the vital melon water extract inhibits the protein expression of PPAR- ⁇ and its target genes.
  • DM differentiation medium
  • DM + DMSO differentiation medium containing various concentrations of vital melon water extract VW (1, 5 and 10 ⁇ g/ml).
  • total protein was extracted with RIPA buffer containing PMSF for 30 minutes on ice.
  • the lysate was centrifuged at 12,000 g at 4° C. for 15 minutes, the total protein concentration of the supernatant was quantified using BioRad protein assay reagent (BioRad, Hercules, CA, USA).
  • liver tissues 50 mg collected from each group were homogenized using PRO-PREPTM Solution (cat. no. 170841; iNtRON Biotechnology Inc., Sungnam, Korea) and centrifuged at 13,000 rpm for 5 minutes. Total protein extract was collected by separation. The protein was then mixed with 4X loading buffer (BioRad, Hercules, CA, USA) and 2-mercaptoethanol (Bioshop, Burlington, Ontario, Canada) and then heated in boiled water for 7 minutes. Next, 12% SDS-PAGE accompanied by a protein marker (BioRad, Hercules, CA, USA) was continuously applied to the prepared protein.
  • PRO-PREPTM Solution catalog. no. 170841; iNtRON Biotechnology Inc., Sungnam, Korea
  • a powder was prepared by mixing the above ingredients and filling in airtight bags.
  • tablets were prepared by tableting according to a conventional tablet manufacturing method.
  • capsules were prepared by filling gelatin capsules according to a conventional capsule preparation method.
  • 5% by weight of honey, 3% by weight of fructose, 0.0001% by weight of sodium riboflavin hydrochloride, 0.0001% by weight of pyridoxine hydrochloride, 86.9998% by weight of water, and 5% by weight of the vital melon extract of the present invention are blended to prepare a health drink in a conventional manner.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • General Health & Medical Sciences (AREA)
  • Botany (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Developmental Biology & Embryology (AREA)
  • Environmental Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Diabetes (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Mycology (AREA)
  • Biotechnology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Medical Informatics (AREA)
  • Microbiology (AREA)
  • Physiology (AREA)
  • Epidemiology (AREA)
  • Nutrition Science (AREA)
  • Food Science & Technology (AREA)
  • Polymers & Plastics (AREA)
  • Child & Adolescent Psychology (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La présente invention concerne un melon vital (KCTC14699BP) et une composition comprenant un extrait de celui-ci en vue de prévenir, de traiter ou de soulager l'obésité ou des troubles liés au métabolisme. Un melon vital de la présente invention subit un ajustement des fruits de sorte que le nombre d'articulations est identique au nombre des ramifications principales et secondaires, et plus de chair des fruits peut être obtenue à partir de celui-ci que à partir d'un melon oriental classique, et ainsi une excellente productivité est fournie, et son extrait peut efficacement inhiber toute accumulation de lipide, le gain de poids, l'accumulation de graisse dans le foie, et similaires, et ainsi peut être efficacement utilisé comme composition de prévention, de soulagement ou de traitement de l'obésité ou de divers troubles liés au métabolisme.
PCT/KR2022/019662 2021-12-10 2022-12-06 Melon vital (kctc14699bp) et composition anti-obésité comprenant un extrait de celui-ci Ceased WO2023106777A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR1020210176404A KR102438938B1 (ko) 2021-12-10 2021-12-10 바이탈멜론 (kctc14699bp) 및 이의 추출물을 포함하는 항비만용 조성물
KR10-2021-0176404 2021-12-10

Publications (1)

Publication Number Publication Date
WO2023106777A1 true WO2023106777A1 (fr) 2023-06-15

Family

ID=83061938

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/KR2022/019662 Ceased WO2023106777A1 (fr) 2021-12-10 2022-12-06 Melon vital (kctc14699bp) et composition anti-obésité comprenant un extrait de celui-ci

Country Status (2)

Country Link
KR (1) KR102438938B1 (fr)
WO (1) WO2023106777A1 (fr)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102438938B1 (ko) * 2021-12-10 2022-08-31 부산대학교 산학협력단 바이탈멜론 (kctc14699bp) 및 이의 추출물을 포함하는 항비만용 조성물

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20050054006A (ko) * 2003-12-03 2005-06-10 주식회사 팬제노믹스 항지방화 및 항비만 활성을 갖는 박과 식물 추출물로부터분리된 화합물을 포함하는 조성물
JP2005289955A (ja) * 2004-03-31 2005-10-20 Cci Corp 肥満および糖尿病の予防および治療剤ならびに食品
JP2013119547A (ja) * 2011-12-06 2013-06-17 Koei Kogyo Kk エストロゲン様組成物
KR101501381B1 (ko) * 2013-10-22 2015-03-12 동의대학교 산학협력단 드라콘토멜론 마크로카펌 추출물을 포함하는 항비만 조성물
KR20200141300A (ko) * 2019-06-10 2020-12-18 부산대학교 산학협력단 비만 예방 또는 치료용 바이탈 멜론 및 이의 추출물
KR102438938B1 (ko) * 2021-12-10 2022-08-31 부산대학교 산학협력단 바이탈멜론 (kctc14699bp) 및 이의 추출물을 포함하는 항비만용 조성물

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20050054006A (ko) * 2003-12-03 2005-06-10 주식회사 팬제노믹스 항지방화 및 항비만 활성을 갖는 박과 식물 추출물로부터분리된 화합물을 포함하는 조성물
JP2005289955A (ja) * 2004-03-31 2005-10-20 Cci Corp 肥満および糖尿病の予防および治療剤ならびに食品
JP2013119547A (ja) * 2011-12-06 2013-06-17 Koei Kogyo Kk エストロゲン様組成物
KR101501381B1 (ko) * 2013-10-22 2015-03-12 동의대학교 산학협력단 드라콘토멜론 마크로카펌 추출물을 포함하는 항비만 조성물
KR20200141300A (ko) * 2019-06-10 2020-12-18 부산대학교 산학협력단 비만 예방 또는 치료용 바이탈 멜론 및 이의 추출물
KR102438938B1 (ko) * 2021-12-10 2022-08-31 부산대학교 산학협력단 바이탈멜론 (kctc14699bp) 및 이의 추출물을 포함하는 항비만용 조성물

Also Published As

Publication number Publication date
KR102438938B1 (ko) 2022-08-31

Similar Documents

Publication Publication Date Title
WO2015002391A1 (fr) Composition présentant une fonction d'atténuation du syndrome prémenstruel et des douleurs menstruelles
WO2016032249A1 (fr) Composition pharmaceutique contenant un extrait de vaccinium bracteatum thunb. ou une fraction de celui-ci comme principe actif pour prévenir ou traiter une inflammation des nerfs ou des maladies neurodégénératives
WO2015111832A1 (fr) Composition de prévention ou de traitement de maladies liées à la prostate, contenant un extrait de poncirus trifoliata
WO2015030293A1 (fr) Composition contenant un extrait composite de raisin et de schisandra chinensis pour la prévention ou le traitement de maladies associées au syndrome métabolique
WO2023106777A1 (fr) Melon vital (kctc14699bp) et composition anti-obésité comprenant un extrait de celui-ci
KR101908221B1 (ko) 금방동사니 추출물을 포함하는 항비만 조성물
WO2020251253A1 (fr) Melon vital pour la prévention ou le traitement de l'obésité et extrait de celui-ci
WO2020242113A1 (fr) Composition pour la prévention, le soulagement ou le traitement du syndrome métabolique accompagné de l'obésité et/ou du diabète, contenant, en tant que principe actif, un complexe (complexe ib) d'extrait de groseille indienne et d'extrait d'orge jeune
WO2016129902A1 (fr) Composition pour prévenir, soulager ou traiter le syndrome d'épuisement professionnel
WO2015194809A1 (fr) Composition à effet immunomodulateur et immunostimulant comprenant un extrait de dendropanax morbifera léveille en tant que principe actif, et son utilisation
WO2013069934A1 (fr) Composition pour traiter et prévenir l'obésité, contenant de l'extrait d'agropyre comme principe actif
WO2021080297A1 (fr) Composition contenant un extrait de fleur d'onagre en tant que principe actif pour prévenir ou traiter l'obésité ou des syndromes métaboliques ainsi induits
WO2018066956A1 (fr) Composition comprenant un extrait composite contenant du schisandrae fructus pour prévenir ou traiter une maladie liée à la circulation sanguine
WO2021080388A1 (fr) Composition pour prévenir ou traiter l'infection par le virus de la diarrhée épidémique porcine, comprenant un complexe contenant un composé à base de curcuminoïde et un extrait de réglisse ou une fraction de celui-ci
WO2016093613A2 (fr) Composition pour la prévention ou le traitement d'une perte de poids anormale, contenant un extrait de pelure de mandarine satsuma
WO2015167240A1 (fr) Composition contenant un extrait de scutellaria alpina
WO2016032250A1 (fr) Composition pharmaceutique contenant un extrait de portulaca grandiflora hook. ou une fraction de celui-ci comme principe actif pour prévenir ou traiter une inflammation des nerfs ou des maladies neurodégénératives
WO2023191249A1 (fr) Composition pour atténuer l'obésité ou le métabolisme des lipides comprenant un extrait d'asimina triloba
WO2012105816A2 (fr) Composition destinée à prévenir et traiter le diabète et les complications du diabète comprenant une poudre d'amphicarpaea edgeworthii var. trisperma ou un extrait de celle-ci
WO2022182199A1 (fr) Composition contenant un extrait à l'eau chaude de cassis pour prévenir, soulager ou traiter les maladies du foie gras non alcooliques
WO2022270760A1 (fr) Méthode de traitement de la stéatohépatite non alcoolique par la co-administration d'un dérivé de la curcumine et d'un inhibiteur du récepteur de tgf-β
WO2023282624A1 (fr) Composition pour prévenir atténuer l'obésité comprenant un extrait d'anchois ou un acide néochlorogénique en tant que principe actif
WO2018106009A1 (fr) Composition comprenant un extrait de feuille d'arbre d'érable ou des fractions de ce dernier destinée à prévenir ou à traiter des maladies oculaires inflammatoires
WO2019078381A1 (fr) Composition pharmaceutique, composition alimentaire et additif alimentaire pour prévenir, soulager ou traiter la perte, la faiblesse et l'atrophie musculaires, contenant, à titre de principe actif, une bactérie enterococcus faecalis, le liquide de culture ou des cellules mortes de celle-ci
WO2020246863A1 (fr) Composition comprenant du chlorhydrate de cudrania comme composant efficace pour soulager, traiter ou prévenir les maladies musculaires, ou améliorer les fonctions musculaires

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 22904607

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 22904607

Country of ref document: EP

Kind code of ref document: A1